STOCK TITAN

Progyny chairman Schlanger sells 35,392 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Progyny, Inc. (PGNY) Executive Chairman David J. Schlanger exercised 35,392 stock options at $0.91 per share on November 10, 2026, acquiring 35,392 common shares and selling 35,392 common shares the same day at a weighted average price of $35.3613 per share. The reported sale prices ranged from $35.01 to $35.71. The sales were made under a Rule 10b5-1 trading plan entered into July 2, 2026. The option transaction reports 32,229 options following the exercise; the options were fully vested and exercisable.

Insider Schlanger David J
Role Executive Chairman
Sold 35,392 shs ($1.25M)
Approx. gross sale proceeds $1.25M
Approx. exercise cost $32K
Approx. pre-tax spread $1.22M
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F3 35,392 $0.00 $0.00
Exercise Common Stock 35,392 $0.91 $32K
Sale Common Stock F1, F2 35,392 $35.3613 $1.25M
Holdings After Transaction: Stock Option (Right to Buy) — 32,229 options (Direct); Common Stock — 238,462 shares (Direct)
Footnotes (3)
  1. F1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. These options are fully vested and exercisable.
Shares sold 35,392 shares Progyny common stock; November 10, 2026
Weighted average sale price $35.3613 per share Sale transactions on November 10, 2026
Sale price range $35.01 to $35.71 per share Multiple sale transactions
Options exercised 35,392 options November 10, 2026
Exercise price $0.91 per share Options exercised on November 10, 2026
Options following transaction 32,229 options Reported after the exercise
Rule 10b5-1 trading plan regulatory
"Shares sold pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
fully vested and exercisable financial
"These options are fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PGNY shares did David J. Schlanger sell and at what price?

David J. Schlanger sold 35,392 Progyny common shares on November 10, 2026, at a weighted average price of $35.3613 per share. The shares were sold in multiple transactions at prices ranging from $35.01 to $35.71 under a Rule 10b5-1 trading plan entered into July 2, 2026.

What PGNY stock options did David J. Schlanger exercise?

Schlanger exercised 35,392 options at $0.91 per share on November 10, 2026, acquiring 35,392 common shares. The option transaction reports 32,229 options following the exercise, and the options were fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schlanger David J

(Last)(First)(Middle)
C/O PROGYNY, INC.
1359 BROADWAY, 2ND FL

(Street)
NEW YORK NEW YORK 10018

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chairman
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/10/2026M35,392A$0.91273,854D
Common Stock11/10/2026S(1)35,392D$35.3613(2)238,462D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.9111/10/2026M35,392 (3)08/03/2027Common Stock35,392$032,229D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. These options are fully vested and exercisable.
Remarks:
/s/ Mark Livingston, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading